Markus Muschen
Overview
Explore the profile of Markus Muschen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
6007
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Z, Zeng C, Yang L, Che Y, Chen M, Sau L, et al.
Cell
. 2024 Dec;
188(2):331-351.e30.
PMID: 39694037
Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth...
2.
Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Muschen M
Cancer Discov
. 2024 Sep;
14(9):1577-1580.
PMID: 39228298
Polatuzumab vedotin, an antibody-drug conjugate targeting CD79B, is the first new drug approved for first-line therapy of diffuse large B-cell lymphoma in more than two decades, although factors determining treatment...
3.
Chan A, Han L, Delaney C, Wang X, Mukhaleva E, Li M, et al.
Sci Adv
. 2024 Feb;
10(8):eadk3127.
PMID: 38394203
Epigenetic dysregulation has been reported in multiple cancers including leukemias. Nonetheless, the roles of the epigenetic reader Tudor domains in leukemia progression and therapy remain unexplored. Here, we conducted a...
4.
Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira A, Pfeuffer L, et al.
Cell Rep
. 2023 Oct;
42(10):113017.
PMID: 37792532
Despite available targeted treatments for the disease, drug-resistant chronic lymphocytic leukemia (CLL) poses a clinical challenge. The objective of this study is to examine whether the dual-specific phosphatases DUSP1 and...
5.
Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, et al.
Nat Cancer
. 2023 Sep;
4(10):1508-1525.
PMID: 37723306
The PDCD1-encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells that is recurrently inactivated in T cell non-Hodgkin lymphomas (T-NHLs). The highest frequencies of PDCD1 deletions...
6.
Ogana H, Hurwitz S, Hsieh C, Geng H, Muschen M, Bhojwani D, et al.
Front Cell Dev Biol
. 2023 Apr;
11:1134121.
PMID: 37082620
As effective therapies for relapse and refractory B-cell acute lymphoblastic leukemia (B-ALL) remain problematic, novel therapeutic strategies are needed. Artemis is a key endonuclease in V(D)J recombination and nonhomologous end...
7.
Li M, Yang L, Chan A, Pokharel S, Liu Q, Mattson N, et al.
Adv Sci (Weinh)
. 2023 Apr;
10(17):e2206584.
PMID: 37075745
Epigenetic dysregulation is reported in multiple cancers including Ewing sarcoma (EwS). However, the epigenetic networks underlying the maintenance of oncogenic signaling and therapeutic response remain unclear. Using a series of...
8.
Cosgun K, Jumaa H, Robinson M, Kistner K, Xu L, Xiao G, et al.
bioRxiv
. 2023 Mar;
PMID: 36993619
Highlights: Unlike other cell lineages, B-cells express nuclear β-catenin protein at low baseline levels and depend on GSK3β for its degradation.In B-cells, β-catenin forms unique complexes with lymphoid-specific Ikaros factors...
9.
Lee J, Robinson M, Sun R, Kume K, Ma N, Cosgun K, et al.
bioRxiv
. 2023 Mar;
PMID: 36993276
Initiation of B-cell receptor (BCR) signaling, and subsequent antigen-encounter in germinal centers represent milestones of B-lymphocyte development that are both marked by sharp increases of CD25 surface-expression. Oncogenic signaling in...
10.
Chen Z, Zhou K, Xue J, Small A, Xiao G, Truong Nguyen L, et al.
Sci Transl Med
. 2023 Mar;
15(689):eabq8513.
PMID: 36989375
Although the overall survival rate of B cell acute lymphoblastic leukemia (B-ALL) in childhood is more than 80%, it is merely 30% in refractory/relapsed and adult patients with B-ALL. This...